Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares traded down 3.4% during trading on Monday. The stock traded as low as $24.86 and last traded at $25.65. 401,641 shares changed hands during mid-day trading, an increase of 702% from the average session volume of 50,104 shares. The stock had previously closed at $26.55.
Neoleukin Therapeutics Stock Performance
The firm has a 50 day simple moving average of $34.84 and a two-hundred day simple moving average of $30.71. The stock has a market cap of $241.06 million, a P/E ratio of -8.25 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc was a biotechnology company focused on developing computationally designed immunotherapies for cancer and other serious diseases. The company used protein-engineering and computational-design technologies to create novel cytokine-based medicines intended to activate the immune system against tumors while potentially reducing some of the limitations associated with naturally occurring cytokines.
Neoleukin’s lead investigational product was NL-201, a designed cytokine mimetic intended to selectively stimulate signaling pathways associated with interleukin-2 and interleukin-15.
Further Reading
- Five stocks we like better than Neoleukin Therapeutics
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
